Schering-Plough today announced that it has completed the acquisition of Organon BioSciences N.V., creating a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Schering-Plough’s agreement to acquire Organon BioSciences was announced on March 12.

“By bringing together complementary businesses, we will be growing even stronger and even better in our people, products and science,” said Fred Hassan, chairman and CEO, Schering-Plough. “The promise of this combination is profound.  We will be working hard to realize that promise – for our customers, for the patients, for our other stakeholders and for our shareowners.”

Organon BioSciences is comprised primarily of Organon, a human health business, and Intervet, an animal health business. It also includes Nobilon, a human vaccine development unit, and Diosynth, a third-party manufacturing unit of Organon. 

Hassan said, “Through this combination we create a powerful science and technology platform. We expand and strengthen Schering-Plough’s late-stage Rx pipeline with five additional promising Phase III compounds. We acquire a robust biologics manufacturing capability that is an excellent match for our earlier-stage biologics projects.  

“With Organon, we expand into two important prescription pharmaceutical franchises, women’s health and central nervous system (CNS),” added Hassan. “These therapeutic areas add to our existing strengths in cardiovascular care, respiratory, immunology and oncology.” 

The transaction also makes Schering-Plough a global leader in animal health through the combination of Schering-Plough Animal Health and Intervet. “We increase our science strength, and we increase our scale in animal health,” said Hassan. “This greatly increases the value we will bring to customers. We see this strong combined animal-health unit as a key strategic part of our integrated business that will contribute to long-term high performance.”

As a result of the combination, Schering-Plough’s leading prescription products will include the Organon products: Follistim/Puregon, a fertility treatment; Zemuron/Esmeron, a muscle relaxant; and Nuvaring and Implanon for contraception. 

The combination also adds five Phase III compounds to Schering-Plough’s existing late-stage projects, building on a rich and promising pipeline. Schering-Plough’s key Phase III projects include:

  • Acadesine, for the prevention of ischemia-reperfusion injury
  • Asenapine (from Organon), a fast-dissolving, sublingual psychopharmacologic agent for the treatment of patients with schizophrenia and acute mania bipolar disorder
  • Corifollitropin alfa (from Organon), a new fertility hormone
  • Golimumab, an anti-inflammatory for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
  • Mometasone / formoterol, for the treatment of asthma
  • NOMAC/E2 (from Organon), an oral contraceptive
  • ORG 50081 (from Organon), for the treatment of insomnia and potentially for hot flashes in menopausal women
  • Sugammadex (from Organon), for the reversal of neuromuscular blockade used as part of general anesthesia during surgical procedures
  • Tablet-based sublingual immunotherapy, for allergies
  • Thrombin receptor antagonist, for acute coronary syndrome and secondary prevention
  • Vicriviroc, for HIV

Schering-Plough’s world headquarters will continue to be in Kenilworth, N.J.  As previously reported, Boxmeer, the Netherlands, will become the headquarters of the global animal health business.

Source: Schering-Plough press release